Carle Paul
Carle Paul
Université Toulouse 3 Paul Sabatier
Verified email at chu-toulouse.fr
Title
Cited by
Cited by
Year
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
CEM Griffiths, K Reich, M Lebwohl, P van de Kerkhof, C Paul, A Menter, ...
The Lancet 386 (9993), 541-551, 2015
6602015
Phase 3 studies comparing brodalumab with ustekinumab in psoriasis
M Lebwohl, B Strober, A Menter, K Gordon, J Weglowska, L Puig, K Papp, ...
New England Journal of Medicine 373 (14), 1318-1328, 2015
6062015
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children
U Wahn, JD Bos, M Goodfield, R Caputo, K Papp, A Manjra, A Dobozy, ...
Pediatrics 110 (1), e2-e2, 2002
4892002
Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study
CF Paul, VC Ho, C McGeown, E Christophers, B Schmidtmann, ...
Journal of investigative dermatology 120 (2), 211-216, 2003
4122003
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
MG Lebwohl, H Bachelez, J Barker, G Girolomoni, A Kavanaugh, ...
Journal of the American Academy of Dermatology 70 (5), 871-881. e30, 2014
4102014
European S3-guidelines on the systemic treatment of psoriasis vulgaris-update 2015-short version-EDF in cooperation with EADV and IPC
A Nast, P Gisondi, AD Ormerod, P Saiag, CH Smith, PI Spuls, ...
Journal of the European Academy of Dermatology and Venereology 29 (12), 2277 …, 2015
3982015
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug
A Kapp, K Papp, A Bingham, R Fölster-Holst, JP Ortonne, PC Potter, ...
Journal of Allergy and Clinical Immunology 110 (2), 277-284, 2002
3772002
Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis
C Paul, P Wolkenstein, H Adle, J Wechsler, HJ Garchon, J Revuz, ...
British Journal of Dermatology 134 (4), 710-714, 1996
3571996
Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding study
P Rich, B Sigurgeirsson, D Thaci, JP Ortonne, C Paul, RE Schopf, ...
British Journal of Dermatology 168 (2), 402-411, 2013
3372013
A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis
KA Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, ...
British Journal of Dermatology 175 (2), 273-286, 2016
3242016
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled …
C Paul, J Cather, M Gooderham, Y Poulin, U Mrowietz, C Ferrandiz, ...
British Journal of Dermatology 173 (6), 1387-1399, 2015
3232015
Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review
C Horreau, C Pouplard, E Brenaut, T Barnetche, L Misery, B Cribier, ...
Journal of the European Academy of Dermatology and Venereology 27, 12-29, 2013
3212013
Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis
FM Arellano, CE Wentworth, A Arana, C Fernández, CF Paul
Journal of Investigative Dermatology 127 (4), 808-816, 2007
3052007
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open …
P Joly, M Maho-Vaillant, C Prost-Squarcioni, V Hebert, E Houivet, S Calbo, ...
The Lancet 389 (10083), 2031-2040, 2017
2832017
The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double‐blind controlled study
C Queille‐Roussel, C Paul, L Duteil, MC Lefebvre, G Rapatz, M Zagula, ...
British Journal of Dermatology 144 (3), 507-513, 2001
2782001
Carcinogenic risks of psoralen UV‐A therapy and narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review
E Archier, S Devaux, E Castela, A Gallini, F Aubin, M Le Maître, ...
Journal of the European Academy of Dermatology and Venereology 26, 22-31, 2012
2672012
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
C Paul, JP Lacour, L Tedremets, K Kreutzer, S Jazayeri, S Adams, ...
Journal of the European Academy of Dermatology and Venereology 29 (6), 1082-1090, 2015
2572015
What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature
E Puzenat, V Bronsard, S Prey, PA Gourraud, S Aractingi, M Bagot, ...
Journal of the European Academy of Dermatology and Venereology 24, 10-16, 2010
2502010
Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study
B Sigurgeirsson, JH Ólafsson, J þ Steinsson, C Paul, S Billstein, ...
Archives of dermatology 138 (3), 353-357, 2002
2452002
Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study
JC Roujeau, B Sigurgeirsson, HC Korting, H Kerl, C Paul
Dermatology 209 (4), 301-307, 2004
2292004
The system can't perform the operation now. Try again later.
Articles 1–20